Impact Factor
2.43
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
0.87
168 total citations
h5-index
22
h5 depth signal
Cited share
32.6%
71 of 218
Total citations
168
Citation footprint
Metric signal
1.11
External metric anchor
Self-citation
0.6%
1 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
Germany
228
China
105
Italy
27
United States
27
Turkey
24
Citing Fields of Research
Oncology
403
Breast Cancer
132
Lung Cancer
110
Hematology
107
Immunology
100
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
5,851
Articles tracked across the journal lifetime
Indexed publication set
218
71 cited publications
Last 12 months
50
4.5 publications/month
Open access share
16.0%
8 OA publications in the last year
Leading citing country
Germany
228 citing publications
Leading citing field
Oncology
403 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v37n1, Feb. 2014-
v37n1, Feb. 2014-
Research Focus & Classification
Indexed Subjects
Oncology
Breast Cancer
Lung Cancer
Immunology
Liver & Colon Cancer
Hematology
Issuing & Sponsoring Bodies
issuing body
Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie
issuing body
Österreichische Gesellschaft für Hämatologie & Medizinische Onkologie
issuing body
Deutsche Fatigue Gesellschaft
issuing body
Deutsche Krebsgesellschaft. Arbeitsgemeinschaft für Internistische Onkologie
Broad Categories
Neoplasms
Lung Cancer
Palliative Care
Digestive Disorders
Breast Cancer
Hematology
Liver & Colon Cancer
MeSH Descriptors
Neoplasms
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1159/ort/aecag010
Open DOI
The risk of radiotherapy toxicity in patients with laryngeal cancer: predictive factors and radiobiological modelling
Introduction: The assessment of post-radiation toxicity and quality of life is a crucial aspect of patient care. To evaluate and predict post-irradiation toxicity in a cohort of patients with laryngeal cancer, radiobiological modelling, ...
02
DOI 10.1159/ort/aecag005
Open DOI
Dose-Dependent Intracranial Response to Sotorasib in KRAS G12C -Mutated Lung Cancer Brain Metastases: A Case Report
Introduction: KRASG12C inhibitors such as sotorasib have expanded precision-oncology options for non-small cell lung cancer (NSCLC). However, central nervous system (CNS) disease control remains a major clinical challenge. Case Presentat...
03
DOI 10.1159/ort/aecag009
Open DOI
Toward Precision Cardio-Oncology: Integrating Biomarkers and Cardiac Imaging for Cardiovascular Risk Assessment in Patients With Cancer
Cardiovascular disease and cancer frequently coexist, and cardiovascular toxicity can limit the delivery of effective anticancer therapy and influence long-term outcomes. Conventional cardiovascular risk scores were not designed for onco...
04
05
DOI 10.1159/ort/aecag007
Open DOI
Comprehensive quality of life assessment in advanced renal cell carcinoma: Final results of the PRO Kidney study
Introduction: Patient-reported outcomes (PROs), particularly health-related quality of life (HRQoL) and treatment-related side effects, are crucial for guiding treatment in advanced renal cell carcinoma (aRCC). We report longitudinal PRO...
06
DOI 10.1159/ort/aecag008
Open DOI
Immunotherapy with Pembrolizumab beyond Progression and Local Ablative Therapy in Oligoprogressive metastatic NSCLC
Background: Immune checkpoint inhibitors (ICIs) targeting PD-(L)1 are standard first-line treatment for non-oncoge-addicted metastatic non-small cell lung cancer (mNSCLC). While disease progression typically requires therapy change, pati...
07
DOI 10.1159/ort/aecag006
Open DOI
Effects of active self-administered and receptive monochord-based sound interventions on cardiovascular parameters and patient-reported symptoms in cancer patients: an exploratory randomized crossover pilot trial
Aim This exploratory, randomized two-period crossover pilot trial evaluated the acute effects of an active (self-administered) body monochord intervention versus a receptive monochord sound-based intervention on cardiovascular parameters...
08
DOI 10.1159/ort/aecag003
Open DOI
Estimating the Proportion of Transplant-Eligible Patients in Diffuse Large B-Cell Lymphoma: Insights from German Hospital Billing Data
Introduction: Treatment, according to guidelines, for second-line and beyond (2L+) therapy of diffuse large B-cell lymphoma (DLBCL) differentiates between transplant-eligible and transplant-ineligible patients. Transplant-eligible patien...
09
Introduction: The combination of venetoclax (VEN) and a hypomethylation agent (HMA) was introduced for the treatment of acute myeloid leukemia (AML) because it achieved significantly better results compared to HMA monotherapy (HMA-mono)....
10
DOI 10.1159/ort/aecag002
Open DOI
Validity of the German Version of the FCR-1r Questionnaire in Patients with Urologic Cancer
Introduction: Fear of cancer recurrence (FCR) is a prevalent and distressing issue for a significant proportion of cancer patients across various disciplines, yet it remains one of the most frequently unaddressed psychosocial needs. A ke...
Bibliographical & Catalog Notes
Also issued online.